| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDPK1 |
| Uniprot No | O15530 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-556aa |
| 氨基酸序列 | MARTTSQLYD AVPIQSSVVL CSCPSPSMVR TQTESSTPPG IPGGSRQGPA MDGTAAEPRP GAGSLQHAQP PPQPRKKRPE DFKFGKILGE GSFSTVVLAR ELATSREYAI KILEKRHIIK ENKVPYVTRE RDVMSRLDHP FFVKLYFTFQ DDEKLYFGLS YAKNGELLKY IRKIGSFDET CTRFYTAEIV SALEYLHGKG IIHRDLKPEN ILLNEDMHIQ ITDFGTAKVL SPESKQARAN SFVGTAQYVS PELLTEKSAC KSSDLWALGC IIYQLVAGLP PFRAGNEYLI FQKIIKLEYD FPEKFFPKAR DLVEKLLVLD ATKRLGCEEM EGYGPLKAHP FFESVTWENL HQQTPPKLTA YLPAMSEDDE DCYGNYDNLL SQFGCMQVSS SSSSHSLSAS DTGLPQRSGS NIEQYIHDLD SNSFELDLQF SEDEKRLLLE KQAGGNPWHQ FVENNLILKM GPVDKRKGLF ARRRQLLLTE GPHLYYVDPV NKVLKGEIPW SQELRPEAKN FKTFFVHTPN RTYYLMDPSG NAHKWCRKIQ EVWRQRYQSH PDAAVQ |
| 预测分子量 | 63,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与PDPK1(又称PDK1)重组蛋白相关的文献摘要概览：
---
1. **文献名称**：*Identification of a Pocket in the PDK1 Kinase Domain that Interacts with PIF and the C-terminal Helix of PKB*
**作者**：Biondi, R.M. et al.
**摘要**：该研究利用重组PDK1蛋白的晶体结构分析，揭示了其激酶结构域中与PKC相关磷酸化位点(PIF pocket)的相互作用机制，解释了PDK1如何通过此结构域识别并磷酸化下游底物(如Akt/PKB)，为靶向PDK1的抑制剂设计提供了结构基础。
2. **文献名称**：*3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro*
**作者**：Alessi, D.R. et al.
**摘要**：通过在大肠杆菌中表达重组PDK1蛋白，作者验证了PDK1在体外和体内对p70 S6激酶的磷酸化激活作用，揭示了其在PI3K/AKT/mTOR信号通路中的核心调控功能，强调了PDK1作为代谢和细胞生长关键调节因子的重要性。
3. **文献名称**：*PDK1 regulates cancer cell motility by antagonizing inhibition of ROCK1 by RhoE*
**作者**：Wilkinson, S. et al.
**摘要**：研究利用重组PDK1蛋白进行体外激酶实验，证明PDK1通过磷酸化RhoE调控ROCK1活性，进而影响肿瘤细胞迁移和侵袭能力，揭示了PDK1在癌症转移中的潜在作用机制。
---
以上文献均涉及重组PDK1蛋白在信号通路解析、结构生物学或疾病机制研究中的关键应用。如需具体文献来源，建议通过PubMed或Web of Science按标题/作者检索获取全文信息。
**Background of PDPK1 Recombinant Protein**
PDPK1 (3-phosphoinositide-dependent protein kinase 1), also known as PDK1. is a serine/threonine kinase that plays a central role in regulating cell survival, proliferation, and metabolism through the PI3K/Akt signaling pathway. It functions as a master upstream kinase by phosphorylating and activating multiple AGC kinase family members, including Akt/PKB, SGK, and certain PKC isoforms. PDPK1's activity is triggered by growth factor signaling, which promotes its recruitment to the cell membrane via interactions with phosphoinositides, enabling it to phosphorylate downstream targets critical for cellular homeostasis. Dysregulation of PDPK1 is linked to cancer, diabetes, and neurodegenerative diseases, making it a therapeutic target of interest.
Recombinant PDPK1 protein is engineered using expression systems like *E. coli* or mammalian cells to produce highly purified, functional kinase for research and drug discovery. This recombinant form typically retains the catalytic domain and critical structural features required for enzymatic activity, allowing studies on its kinase mechanism, substrate interactions, and inhibitor screening. It is widely used in *in vitro* assays to investigate PI3K/Akt pathway dynamics, validate drug candidates targeting oncogenic signaling, and explore metabolic disorders.
The development of PDPK1 recombinant protein has advanced structural studies, revealing conformational changes during activation and guiding the design of selective inhibitors. Its application extends to biomarker studies, where aberrant PDPK1 expression correlates with tumor progression and therapy resistance. By providing a consistent and scalable source of active kinase, recombinant PDPK1 supports both basic research and preclinical development, bridging mechanistic insights into cellular signaling with therapeutic innovation.
×
